EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway

Dan Shu iD, Lin Cheng, Kefei Yuan, Dan Liu, He Wei

Antiviral Therapy · 2023

DOI: 10.1177/13596535231219639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, 2023. Verfasst von Dan Shu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioscience and Technology, Chengdu Medical College, Chengdu, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Apolipoprotein A-I. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University, the Science and Technology Major Program of Sichuan Province, 2021 annual foundation of Chengdu Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previously, we have demonstrated that Apolipoprotein A-I (ApoA-I) could inhibit the secretion of Hepatitis B virus (HBV), suggesting that stimulation of ApoA-I may block particle production. In the present study, we evaluated the anti-HBV effect of RVX-208, a small-molecule stimulator of ApoA-I gene expression.

Methods

RVX-208 was used to treat HepG2.2.15 cell, a HepG2 derived cell line stably producing HBV virus. Real-time PCR was performed to examine the HBV DNA levels. Magnetic particles, which were coated with anti-HBS or anti-HBE antibody, were used to examine the HBsAg and HBeAg levels in the supernatant of cultured HepG2.2.15 cells in combination with the enzyme conjugates that were prepared with horseradish peroxidase labelled anti-HBS or anti-HBE antibody in a double antibody sandwich manner. RNA-seq, immunoblots and real-time PCR were used to analyze the functional mechanism of RVX-208.

Results

RVX-208 could elevate the ApoA-I protein levels in HepG2.2.15 cells. In the meantime, RVX-208 significantly repressed HBV DNA, HBsAg and HBeAg levels in the supernatants of HepG2.2.15 cells. RNA-seq data revealed that RVX-208 treatment not only affected the cholesterol metabolism, which is closely related to ApoA-I, but also regulated signalling pathways that are associated with antiviral immune response. Moreover, mechanistic studies demonstrated that RVX-208 could activate cGAS-STING pathway and upregulate the transcription of a series of interferons, pro-inflammatory cytokines and chemokines with antiviral potential that are at the downstream of cGAS-STING pathway.

Conclusion

Our study demonstrated that RVX-208, an inducer of ApoA-I, could suppress HBV particle production through activation of cGAS-STING pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusApolipoprotein A-IHumansHepatitis B Surface AntigensDNA, ViralHepatitis B e AntigensHep G2 CellsNucleotidyltransferasesQuinazolinones

Stichwörter der Autor:innen

RVX-208antiviral therapyapolipoprotein A-IcGAS-STING pathwayhepatitis B virusinterferons

Substanzen

Apolipoprotein A-IHepatitis B Surface AntigensDNA, ViralHepatitis B e AntigensNucleotidyltransferasesapabetaloneQuinazolinones

Autor:innen und Institutionen

  • School of Bioscience and Technology, Chengdu Medical College, Chengdu, China.
  • School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Liver Surgery & Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.
  • Department of TCM, Sichuan Province People's Hospital, Sichuan Academy of Medical Sciences, Chengdu, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, China.

ORCID-Profile: Dan Shu

Förderung

  • 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
  • the Science and Technology Major Program of Sichuan Province
  • 2021 annual foundation of Chengdu Medical College

Zitieren

APA

Shu, D., Cheng, L., Yuan, K., Liu, D., & Wei, H. (2023). RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway. Antiviral Therapy. https://doi.org/10.1177/13596535231219639

Vancouver

Shu D, Cheng L, Yuan K, Liu D, Wei H. RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway. Antiviral Therapy. 2023. doi:10.1177/13596535231219639

BibTeX
@article{Shu2023,
  author = {Shu, Dan and Cheng, Lin and Yuan, Kefei and Liu, Dan and Wei, He},
  title = {RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway},
  journal = {Antiviral Therapy},
  year = {2023},
  doi = {10.1177/13596535231219639}
}
Kostenlos starten →